1. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab

   • Gregory Klein
   • P. Delmar
   • R. Doody

   Brief Reports Open access 03 December 2020 Pages: 3 - 6

   

2. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer’s Disease Dementia: Results From a Phase 2 Randomized Clinical Trial

   • Margaret Moline
   • S. Thein
   • S. Dhadda

   Original Research Open access 03 December 2020 Pages: 7 - 18

   

3. Assessing the Impact of Factors that Influence the Ketogenic Response to Varying Doses of Medium Chain Triglyceride (MCT) Oil

   • Angela G. Juby
   • D. R. Brocks
   • D. R. Mager

   Original Research 09 October 2020 Pages: 19 - 28

   

4. Long Chain Omega-3 Fatty Acid Intervention in Ageing Adults at Risk of Dementia Following Repeated Head Trauma. Low-Level Support or an Opportunity for an Unanswered Question?

   • C. S. Patch
   • E. L Hill-Yardin
   • Alan J. Pearce

   Brief Reports 14 September 2020 Pages: 29 - 32

   

5. Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia: One-Year Partner Outcomes

   • P. A. Amofa
   • Dona E. C. Locke
   • G. E. Smith

   Original Research 26 October 2020 Pages: 33 - 40

   

6. Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults

   • Wan-Hsuan Lu
   • K. V. Giudici
   • MAPT/DSA Group

   Original Research 28 October 2020 Pages: 41 - 47

7. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer’s Disease in Down Syndrome

   • Michael S. Rafii
   • S. Zaman
   • B. L. Handen

   Brief Reports 19 June 2020 Pages: 48 - 51

   

8. Is Reluctance to Share Alzheimer’s Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?

   • Chelsea G. Cox
   • M. M. Ryan
   • J. D. Grill

   Original Research 27 June 2020 Pages: 52 - 58

   

9. The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial

   • Kathryn V. Papp
   • D. M. Rentz
   • A4 Study Team

   Original Research Open access 05 July 2020 Pages: 59 - 67

   

10. Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer

    • M. Milà-Alomà
    • G. Salvadó
    • ALFA study

    Original Research Open access 29 September 2020 Pages: 68 - 77

    

11. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer’s Disease

    • P. Daunt
    • C. G. Ballard
    • for the Alzheimer’s Disease Neuroimaging Initiative

    Original Research Open access 11 November 2020 Pages: 78 - 83

    

12. A Systematic Review on the Feasibility of Salivary Biomarkers for Alzheimer’s Disease

    • M. Bouftas

    Original Research 25 October 2020 Pages: 84 - 91

    

13. Physical Fitness and Apolipoprotein E Genotype Influence Cortical Networking and Intelligence in Adolescents

    • J. Park
    • Y. Kim
    • M. Woo

    Original Research 19 October 2020 Pages: 92 - 99

    

14. The Effect of Baseline Performance and Age on Cognitive Training Improvements in Older Adults: A Qualitative Review

    • J. S. Shaw
    • S. M. Hadi Hosseini

    Reviews 19 October 2020 Pages: 100 - 109

    

15. Nutrition to Prevent or Treat Cognitive Impairment in Older Adults: A GRADE Recommendation

    • F. Buckinx
    • Mylene Aubertin-Leheudre

    Reviews 07 August 2020 Pages: 110 - 116

16. Developing a Skilled Workforce: Impact of a Postgraduate Programme on Dementia Knowledge, Attitudes and Training Needs

    • Charles Scerri

    Letter to the Editor 07 October 2020 Pages: 117 - 118